Get the Stockscreener App
63.96
3.50%
2.16
After Hours:
63.92
-0.04
-0.06%
Moderna Inc stock is traded at $63.96, with a volume of 24.04M.
It is up +3.50% in the last 24 hours and up +32.95% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$61.80
Open:
$63.96
24h Volume:
24.04M
Relative Volume:
3.47
Market Cap:
$25.38B
Revenue:
$2.23B
Net Income/Loss:
$-3.19B
P/E Ratio:
-7.8515
EPS:
-8.1462
Net Cash Flow:
$-1.60B
1W Performance:
+28.85%
1M Performance:
+32.95%
6M Performance:
+106.66%
1Y Performance:
+151.81%
1-Day Range:
$60.73
$67.74
1-Week Range:
$49.62
$67.74
52-Week Range:
$22.28
$67.74
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
63.96 | 24.52B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
451.63 | 116.49B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
609.94 | 63.73B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.72 | 55.49B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.09 | 37.75B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
162.99 | 33.54B | 742.00K | -1.37B | -1.07B | -7.0731 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
FDA panel gives nod to Moderna flu shot - The Hill
Moderna seeks FDA approval for its new flu shots that us MRNA technology - CBS News
FDA panel recommends mRNA flu vaccine for older adults - The Hill
Moderna (MRNA) Receives Unanimous Support for Seasonal Flu Vacci - GuruFocus
FDA panel backs first-of-its-kind flu vaccine using mRNA technology - WRAL
MRNA Stock Clocks Best Week In Over 4 Years On FDA Advisory Committee Endorsement For Flu Vaccine - TradingView
🔎 Under the Radar: Moderna Stock Rises on Flu-Shot Recommendation - WSJ
Moderna gains unanimous FDA panel endorsement of flu vaccine - Seeking Alpha
FDA panel backs Moderna’s flu vaccine for older adults - Investing.com
Doctor explains Moderna's candidate for first MRNA flu shot - WCVB
Moderna options trading surges to 121,257 contracts today By Investing.com - Investing.com Nigeria
Moderna (MRNA) Receives Positive Advisory Committee Vote for Inf - GuruFocus
Moderna (MRNA) Receives Positive FDA Advisory Votes for Flu Vacc - GuruFocus
FDA panel recommends Moderna’s mRNA flu shot for older adults - AOL.com
Moderna (MRNA) Shares Rise Following FDA Advisory Committee Appr - GuruFocus
Moderna’s mRNA Flu Vaccine Wins FDA Advisory Committee Backing - Bloomberg.com
FDA Votes in Favor of Benefit-Risk Profile for Moderna’s Flu Vaccine - WSJ
FDA panel backs Moderna’s flu vaccine for older adults By Investing.com - Investing.com Canada
FDA advisers back Moderna's flu vaccine for older adults, 9-0 - Stock Titan
Moderna Secures Favorable FDA Panel Recommendation for mRNA Flu Vaccine - marketscreener.com
Moderna (MRNA) Flu Vaccine Benefits Confirmed by FDA Advisers - GuruFocus
MRNA (NASDAQ) Form 144 shows 25,770-share option exercise, prior 36,759 sale - Stock Titan
Bulls Pile Into Moderna As FDA Decision Nears, Ignites 60% Surge In This ETF - Benzinga
US FDA advisers vote in favor of Moderna's flu vaccine - Reuters
Moderna options trading surges to 121,257 contracts today - Investing.com
FDA panel considers a first-of-its-kind flu vaccine using mRNA technology - KFOR
Moderna just got a signal investors can’t ignore - Yahoo Finance
Moderna's mRNA flu vaccine faces FDA advisory panel scrutiny - TradingView
Table turned, Moderna’s high-fi flu shot plays well at adcom - BioWorld News
First-of-its-kind flu vaccine could be coming as FDA panel weighs historic shot - New York Post
Moderna Extends Rally as FDA Advisory Panel Reviews Flu Vaccine Application (MRNA) - Yahoo Finance
Moderna mulls deals to rescue German BioNTech plants from closure: report - BioSpace
First-of-its-kind flu shot may be approved for older adults - NewsNation
FDA to consider Moderna’s new mRNA flu vaccine | Morning in America - NewsNation
The Escalator: Moderna, CMI Media Group, Commonweal Ventures and more - Medical Marketing and Media
Moderna's mRNA flu vaccine backed by FDA advisers - marketscreener.com
Eversept Partners LP Invests $7.90 Million in Moderna, Inc. $MRNA - MarketBeat
Moderna Stock Rockets 34% With 5-Day Winning Streak - Trefis
These 3 Stocks Have Crushed the Market This Year. Here's Why There Is More Upside Ahead - The Motley Fool
Moderna’s 12% Rally Puts Flu Shot Catalyst Back at Center Stage - FXLeaders
Moderna (MRNA) Soars 11% Ahead of Investor Day - Yahoo Finance
FDA vaccine panel set to review Moderna mRNA flu shot - The Hill
Insider Selling: Moderna (NASDAQ:MRNA) President Sells 53,336 Shares of Stock - MarketBeat
Moderna Stock Jumps As Restructuring And Flu Catalyst Draw Traders - timothysykes.com
Moderna president exercises options, sells 53K shares | MRNA Insider Trading - Stock Titan
Moderna (NASDAQ:MRNA) Reaches New 1-Year HighStill a Buy? - MarketBeat
Moderna stock hits 52-week high at $59.57 - Investing.com
Analysts Conflicted on These Healthcare Names: Moderna (MRNA) and Scienture Holdings (SCNX) - The Globe and Mail
MRNA Stock Jumps as FDA Briefing Docs Ease Flu Shot Approval Concerns - Yahoo Finance
FDA Files Concerns Over Missing Data for Moderna’s mRNA Flu Shot: Report - PharmExec.com
Moderna Stock Surges As Federal Health Regulators Clear Milestone Older Adult Flu Vaccine Data - TIKR.com
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
2.84%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):